nektar therapeutics (NKTR:NASDAQ GS)
Earnings & Estimates Summary - NEKTAR THERAPEUTICS (NKTR)
2013 revenues at Nektar Therapeutics totaled $148.9M USD, while annual losses equaled $1.40 per share.
Quarterly Earnings & Estimates - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Quarterly Earnings
Nektar Therapeutics reported 2nd quarter 2014 losses of $0.26 per share on 08/2/2014.
Annual Earnings & Estimates - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Annual Earnings
Nektar Therapeutics reported annual 2013 losses of $1.40 per share on 02/28/2014.
Quarterly Revenues - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Quarterly Revenues
Nektar Therapeutics had 2nd quarter 2014 revenues of $28.5M USD. This bettered the $19.8M USD consensus of the 8 analysts covering the company. This was -15.8% below the prior year's 2nd quarter results.
Annual Revenues - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Annual Revenues
Nektar Therapeutics had revenues for the full year 2013 of $148.9M USD. This was 83.4% above the prior year's results.
|Depomed Inc||$15.69 USD||+0.145|
|Emergent Biosolutions Inc||$27.93 USD||+0.29|
|Ironwood Pharmaceuticals Inc||$14.95 USD||+0.38|
|Synergy Health PLC||2,031 GBp||-45.00|
|Theravance Inc||$15.03 USD||+0.48|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|